Paul has 20 years of industry experience. Although trained in internal medicine and pathology, Idelevich has largely remained focused on basic cell biology, as it applies to disease states and the aging process. Prior to forming Prescient Pharma, Idelevich’s work has led to the isolation and identification of rare circulating fetal and tumor cells, currently in development by EarlyCell.